Post-earnings recap
Reported
Thu, Aug 2, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss of $0.40 per share, but did not provide revenue figures or any guidance updates. The stock reacted negatively, dropping 3.09%, indicating investor concern over the lack of financial clarity and future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.